Company / Cash & Equivalents
Citius Pharmaceuticals, Inc. Cash & Equivalents History
FY2011-FY2013 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$54.4K
FY2013
5-year range
$212 / $54.4K
FY2011-FY2013
Trend
+30.6%
vs FY2012
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $212 to $54,390 over the past 2 years.
Based on SEC 10-K filings.
$54,390 in FY2013.
Improved from $212 to $54,390 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2013, cash & equivalents increased 30.6% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2013 | $54.4K | +30.6% |
| FY2012 | $41.7K | +19549.1% |
| FY2011 | $212 | - |
As of FY2013 · SEC 10-K · Updated Jun 22, 2026